Exploratory study on the safety of oral administration of dapagliflozin for renal dysfunction in patients with unilateral nephrectomy

Phase 2

Recruiting

• Conditions: renal dysfunction; Chronic renal failure; D007676

• Registration Number: JPRN-jRCT1031220661
• Lead Sponsor: Yamada Daisuke

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-02-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Patients with unilateral nephrectomy (regardless of time since nephrectomy)
2. Patients with an eGFR of 25-59mL/min/1.73m2 for more than 3 months
3. Age: Those who are between 18 and 85 years of age at the time of obtaining consent
4. Male or female
5. Those who have received a full explanation of the study and have given written consent of their own free will based on a full understanding of the study
6. Those who can make outpatient visits in accordance with the research implementation schedule

Exclusion Criteria

1. Patients who need treatment such as anticancer drugs
2. Patients with active renal or systemic inflammation
3. Those who are allergic to dapagliflozin
4. Those who are pregnant or may become pregnant
5. Those who are breastfeeding
6. Those who are judged inappropriate for participation in this study by the principal investigator or co-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified